Maintenance and Improvement of Skin Clearance Response With Brodalumab 
Among Patients With Moderate-to-Severe Psoriasis

Neal D. Bhatia,1 Seemal R. Desai,2 Craig Teller,3 Abby Jacobson4
1Therapeutics Clinical Research, San Diego, CA; 2Innovative Dermatology, PA, Plano, TX, The University of Texas Southwestern Medical Center, Dallas, TX; 3Bellaire Dermatology, Bellaire, TX; 4Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ

39th Annual Fall Clinical Dermatology Conference® for Dermatologists • October 17-20, 2019 • Las Vegas, NV

INTRODUCTION 

• Brodalumab is a human anti–interleukin-17 receptor A monoclonal antibody 
that is efficacious in treating moderate-to-severe psoriasis1

• Maintenance of skin clearance among patients receiving brodalumab 210 mg 
subcutaneously every 2 weeks (Q2W) stratified by categories of psoriasis 
area and severity index (PASI) response at 12 weeks was previously 
assessed in two phase 3 studies (AMAGINE-2/-3) of adults with moderate-
to-severe plaque psoriasis2

OBJECTIVE 

• To evaluate skin clearance response with brodalumab 210 mg Q2W 
through week 52 in the phase 3, double-blind, randomized, placebo-
controlled AMAGINE-1 trial 

METHODS

• Patients in AMAGINE-1 were initially randomized to brodalumab 210 mg 
Q2W or placebo for 12 weeks3

• After 12 weeks, those receiving brodalumab 210 mg Q2W who achieved 
static physician’s global assessment score of 0 or 1 (sPGA 0/1) were 
re-randomized to brodalumab 210 mg Q2W or placebo

• Beginning at week 16, patients re-randomized to placebo who had return of 
disease, defined as sPGA ≥3, qualified for retreatment with their induction 
dose of brodalumab

• 128 patients from AMAGINE-1 who received continuous brodalumab 210 mg 
Q2W through week 52 were included in this post hoc analysis comprising 

 – 83 patients who were re-randomized to brodalumab 210 mg Q2W 
 – 45 non–re-randomized patients who received brodalumab 210 mg Q2W after 

inadequate sPGA response
• Skin clearance was monitored by categories of PASI response using 

nonresponder imputation

RESULTS

Week 12 PASI Responses
• At week 12, among 128 patients who received continuous brodalumab  

210 mg Q2W, 63% achieved PASI 90% improvement (PASI 90) or greater 
(37% achieved PASI 100 and 26% achieved PASI 90 to <100; Table 1)

PASI Responses at Weeks 16, 28, and 52
• Among patients achieving PASI 100 at week 12, >75% maintained PASI 100  

at weeks 16 and 28 
 – 81% maintained PASI 100 at week 16
 – 77% maintained PASI 100 at week 28

• Among patients achieving PASI 100 at week 12, 79% maintained PASI 100 
through week 52

• Notably, most patients (64%) who achieved PASI 90 to <100 at week 
12 either improved to PASI 100 (49%) or maintained the same level of 
clearance (15%; Figure 1) at week 52

• Of patients who achieved PASI 75 to <90 at week 12, 43% experienced 
improvement at week 52 (19% improved to PASI 100 and 24% improved to 
PASI 90 to <100)

Acknowledgments: This study was sponsored by Ortho Dermatologics. Medical writing support was provided by  
MedThink SciCom and funded by Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US, LLC.

References: 1. Siliq [package insert]. Valeant Pharmaceuticals North America LLC; 2017. 2. Strober et al. Poster 
presented at: 76th Annual Meeting of the American Academy of Dermatology; February 16-20, 2018; San Diego, CA.  
3. Papp et al. Br J Dermatol. 2016;175:273-286.

© 2019. All Rights Reserved.

Table 1. PASI Response at Week 12 in AMAGINE-1  

3
6

9

15

49

18

Responses at week 52 among week 12 
PASI 90 to <100 responders, %

PASI <50

PASI 50 to <75

PASI 75 to <90

PASI 90 to <100

PASI 100

Othera Among PASI 90 to
<100 responders at week 12,

most (64%) improved to
PASI 100 (49%) or

maintained the same level
of response (15%)

Figure 1. PASI responses at week 52 among patients receiving  
brodalumab 210 mg Q2W who achieved PASI 90 to <100 at week 12. 

PASI, psoriasis area and severity index; Q2W, every 2 weeks. aOther includes 6 patients who discontinued before 
week 52 (n=2), those who received retreatment after return of disease (static physician’s global assessment score 
≥3) at or after week 16 (n=3), and those with missing data (n=1).

 

CONCLUSIONS

• These data demonstrate maintenance and continued 
improvement of skin clearance through week 52  
with brodalumab 

Response at week 12, n (%)
Continuous brodalumab 210 mg Q2W

(N=128)

PASI 100 47 (37)

PASI 90 to <100 33 (26)

PASI 75 to <90 21 (16)

PASI 50 to <75 11 (9)

PASI <50 16 (13)

PASI, psoriasis area and severity index; Q2W, every 2 weeks.